Effect on insulin clearance of different pharmacological treatments in women with polycystic ovary syndrome: a hypothesis-generative study
Abstract
PURPOSE: Impaired insulin clearance has been found in women with PCOS and contribute to generate hyperinsulinemia in these subjects. However, the mechanisms underlying this phenomenon remain unknown. The aim of this retrospective study was to explore if the heterogeneous treatments used in these patients to counteract their hormonal and metabolic alterations can also affect insulin clearance.
METHODS: Forty-seven women with PCOS were included in the study. They belonged to different experimental groups, submitted to treatments with the following drugs: GnRH-agonist (buserelin, n = 10), antiandrogens (spironolactone, n = 9), metformin (n = 18), or placebo (n = 10). Metabolic clearance rate of insulin (MCRI) and insulin sensitivity were measured by the hyperinsulinemic euglycemic clamp, performed before and after treatment. Insulin secretion was estimated by the HOMA β-index.
RESULTS: Treatments were associated, as expected, with different clinical effects. In ANOVA analysis, changes in MCRI significantly differed between treatment groups. In particular, metformin increased MCRI as compared with other treatments or placebo. Mediation analysis showed that about 25% of this effect of metformin was mediated by the concurrent BMI change, whereas it was not influenced by changes in peripheral insulin sensitivity or insulin secretion.
CONCLUSION: The impairment of MCRI, which contributes to the hyperinsulinemia typical of PCOS, significantly improved after treatment with metformin.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 18 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.